U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.

Cover of LiverTox

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].

Show details

Meetings and News

Last Update: April 1, 2022.

Conferences and Meetings

Conferences and Meetings in 2021 (Archives) – 2022

THE LIVER MEETING® 2022

November 4-8, 2022

A Hybrid Event Hosted in Washington, DC

Sponsored by the American Association for the Study of Liver Diseases (AASLD), the Meeting has a focus on the science and clinical practice of hepatology, providing the latest information on hepatology research and patient care. Hepatologists from around the world exchange the latest research, discuss new developments in treatment outcomes, and network with other experts in the field.

THE AASLD/FDA DILI CONFERENCE — Drug-induced Liver Injury:

New Developments and Innovations in Patients with Underlying Liver Disease, Cancer or COVID-19

April 20-22, 2021

Sponsored by the American Association for the Study of Liver Diseases (AASLD) and the Food and Drug Administration, the Conference will connect international academic, industry and government participants who are dedicated to the study of DILI in chronic liver disease and cancer with topics spanning into innovative tools in the assessment of hepatotoxic risk and the growing number of best practice consensus reports by public-private partnerships management of DILI in different study populations. Additionally, the meeting will have planned sessions on the impact of COVID-19 in the evaluation and management of liver disease. With virtual communication tools, the conference will promote interactivity between faculty and the audience by with panel discussions and a live poster session.

Session I: Strategies to Identify, Assess and Manage Hepatotoxicity in Clinical Trials for Treatment of CLD

Session II: Liver Injury Scenarios with COVID-19

Session III: Innovative Tools to Predict and Diagnose DILI

Session IV: Cancer Drugs and Hepatotoxicity

Session V: Perspectives in the Development of Best Practices for Different DILI Scenarios

Session VI: DILI: One Four Letter Word, Multiple Phenotypes: Case Presentations and Discussion

HEPATOTOXICITY SPECIAL INTEREST GROUP (SIG) SEMINARS

Sponsored by the American Association for the Study of Liver Diseases

SIG Chair: Adrian Reuben, MBBS, FRCP, FACG, FAASLD AGAF

January 13, 2022, 11:00am–12:00pm EST

Dr. Udayan Apte, Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center

Mechanisms of liver regeneration after drug-induced liver injury – an update.

Registration Link: https://bit.ly/DILI01-22

February 10, 2022, 11:00am–12:00pm EST

Dr. Paul “Skip” Hayashi. DILI Team Lead, Division of Hepatology & Nutrition, Office of New Drugs, Food and Drug Administration

RECAM, An evidence-based update of the RUCAM based on DILIN and Spanish Registry data.

Registration Link: https://bit.ly/DILI02-22

March 10, 2022, 11:00am–12:00pm EST

Ge Lin, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong

Pyrrolizidine alkaloids (PA)-induced liver injury via ingestion of PA-containing herbs and PA-contaminated foodstuffs.

Registration Link: https://bit.ly/DILI03-22

April 14, 2022, 11:00am–12:00pm EDT

Dr. Harmeet Malhi, Mayo Clinic Alix School of Medicine, Rochester, MN

Extracellular vesicles in hepatocellular stress responses – biogenesis, secretion and signaling responses in lipotoxicity and alcohol models.

Registration Link: https://bit.ly/DILI04-22

May 12, 2022, 11:00am–12:00pm EDT

Dr. José Carlos Fernández-Checa, Dept of Cell Death and Proliferation, Institute of Biomedical Research of Barcelona, Spain

The role of steroidogenic acute regulatory protein (STARD1), a mitochondrial cholesterol transporter, in drug-induced liver injury.

Registration Link: https://bit.ly/DILI05-22

June 9, 2022, 11:00am–12:00pm EDT

Dr. Maria L Martinez-Chantar, Liver Disease Lab University of Deusto, School of Medicine, Derio, Spain

Restoring cellular magnesium balance through Cyclin M4 protects against Acetaminophen-induced liver injury. Registration Registration Link: https://bit.ly/DILI06-22

September 8, 2022, 11:00am–12:00pm EDT

Dr. Steven G Rozen, Duke-NUS Medical School, Singapore

Aristolochic acid in herbal remedies is a common cause of liver cancer.

Registration Link: https://bit.ly/DILI09-22

October 13, 2022, 11:00am–12:00pm EDT

Dr. Xiaochao Ma. Center for Pharmacogenetics, School of Pharmacy, University of Pittsburgh

Metabolomics provides novel insights into the mechanisms of DILI associated with anti-TB/HIV drugs.

Registration Link: https://bit.ly/DILI10-22

December 8, 2022, 11:00am–12:00pm EST

Dr. Hans Tillmann, Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, East Carolina University, Greenville, NC

Current causality assessment of drug-induced liver injury: challenges and future directions.

Registration Link: https://bit.ly/DILI12-22